Clinical Trials Logo

Arthritis clinical trials

View clinical trials related to Arthritis.

Filter by:

NCT ID: NCT03890302 Completed - Clinical trials for Rheumatoid Arthritis

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

Start date: March 14, 2019
Phase: Phase 1
Study type: Interventional

The cause of Rheumatoid Arthritis (RA) is not fully understood. However, one of the substances secreted by certain cells in the body, interleukin-6 (IL-6), is believed to play a major role in chronic inflammation that is typical in RA. This study investigates the drug FB704A, which is believed to lower the inflammation caused by IL-6. This study will be in 2 sequential parts: a single increasing dose part (Part 1) and a multiple-increasing dose part (Part 2). Subjects will receive either active or placebo drug by IV infusion. Subjects in both parts will have a short stay in the clinic at the start of the study, then will return for outpatient visits.

NCT ID: NCT03886142 Completed - Pain, Chronic Clinical Trials

Platelet Rich Plasma Versus Radio Frequency for Chronic Knee Arthritis

Start date: September 27, 2018
Phase: N/A
Study type: Interventional

Osteoarthritis (OA) affects aged above 45 years. RF has been used for several painful conditions. There have been a few attempts to use RF current for the treatment of painful conditions of joints of the extremities. It was also used for the treatment of painful conditions of the hip joint.

NCT ID: NCT03885037 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)

Start date: March 20, 2019
Phase:
Study type: Observational

To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against rheumatoid arthritis under actual status of use.

NCT ID: NCT03882008 Completed - Clinical trials for Rheumatoid Arthritis

A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis

Start date: May 23, 2019
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to evaluate if baseline levels of T cell associated biomarkers predict efficacy of abatacept during 24 weeks of treatment in patients with moderate to severe active Rheumatoid Arthritis (RA) who have had an inadequate response to conventional disease modifying anti-rheumatic drugs (cDMARDs)

NCT ID: NCT03881059 Completed - Clinical trials for Active Psoriatic Arthritis

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.

NCT ID: NCT03876210 Completed - Arthritis Clinical Trials

Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Start date: July 12, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the safety and pharmacokinetics of PK101(fixed-dose combination of PK101-001 and PK101-002) with coadministration of the two separate drugs in healthy volunteers.

NCT ID: NCT03868072 Completed - Clinical trials for Rheumatoid Arthritis

Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers

Start date: February 22, 2019
Phase: Phase 1
Study type: Interventional

This study is an open-label, randomized, fasted, single dose, crossover study to evaluate the bioequivalence of Chong Kun Dang Pharmaceutical "Chong Kun Dang Tofacitinib Tablet" and Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in healthy volunteers

NCT ID: NCT03863405 Recruiting - Clinical trials for Rheumatoid Arthritis

Metformin Use in Rheumatoid Arthritis

Start date: January 9, 2019
Phase: Phase 2
Study type: Interventional

Metformin has been used clinically for over 50 years, as a glucose lowering agent. Direct and indirect anti-inflammatory effects of metformin have been reported in animal and clinical studies, and this effect is independent of its hypoglycemic effect. Animal studies showed that metformin decreased serum C-reactive protein (CRP) level in atherogenic rabbits and decreased proinflammatory cytokines (interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF-α) in obese mice . Moreover, metformin also suppressed osteoclastogenesis ; this may partially result from decreased expression of inflammatory cytokines that promote osteoclastogenesis in the arthritic joint. The objective of this study is to evaluate the efficacy and safety of addition of metformin to standard disease modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis.

NCT ID: NCT03858725 Completed - Clinical trials for Rheumatoid Arthritis

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers

Start date: February 26, 2019
Phase: Phase 1
Study type: Interventional

This study is a randomized, open-label, fasted, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-374 5 mg in healthy volunteers.

NCT ID: NCT03858504 Completed - Clinical trials for Enthesitis Related Arthritis

Yoga Versus Home Exercise Program in Children With Enthesitis Related Arthritis

Start date: July 31, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to compare the effectiveness of different exercises programs as 'Yoga' and 'Home Exercise' in Enthesitis Related Arthritis.